Coronavirus disease (COVID-19) 2020

[Hollow Knight]

OK. I'm really sorry I brought any of this up.

Let's leave it at that but perhaps keep in mind what I've said and we might revisit it in a few months.

As we wait 5-8 years for a vaccine. We’ll keep an eye on that too.

 

[martinson]

You have still not actually given any sources whatsoever.

For example, not this study post-exposure (so, very early-stage) hydroxychloroquine, which found no significant difference in whether subjects were went on to get the coronavirus:

https://www.nejm.org/doi/full/10.1056/NEJMoa2016638

Or this study (a pre-coronavirus study) which founds that that combination of drugs led to a substantially increased risk of heart attacks:

WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19

May 27, 2020 — Two of the front-line drugs being used to treat COVID-19 (SARS-CoV-2) patients are hydroxychloroquine and azithromycin, but a new study shows these drugs in combination may pose a serious impact on the cardiovascular system and are a potentially lethal combination. Both drugs...

www.dicardiology.com

I need to end it but that was about prevention after exposure, which obviously it cannot . It's not a preventative treatment.

As far as WHO studies go I think there's more than enough evidence out there that the organisation is questionable in the information it feeds out.

 

[dlanod]

COVID can be treated by a rum and coke a day.

I have done a heap of research.

I won't tell you what I used for my research.

Believe me.

 

[martinson]

Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949

www.sciencedirect.com

Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?

The severity of COVID-19 has resulted in a global rush to find the right antiviral treatment to conquer the pandemic and to treat patients. This requi…

www.sciencedirect.com

Chloroquine genius Didier Raoult to save the world from COVID-19

As COVID19 pandemic rages on, French microbiologist Didier Raoult offers a cure. President Trump is convinced, but is Raoult’s research reliable, here and in general?

forbetterscience.com

Summary of the various post-study reviews:

all the ways the influential hydroxychloroquine study was crap - Gizmodo

We come from the future.

www.gizmodo.co.uk

Btw.

There is a political war going on in the US about whether Trump was right or wrong.

There are literally tens of thousands of articles debunking him as you'd expect . And everyone who hates him, which is many people, swallow it.

I've got no interest in that side of it.

 

[Hollow Knight]

Btw.

There is a political war going on in the US about whether Trump was right or wrong.

There are literally tens of thousands of articles debunking him as you'd expect . And everyone who hates him, which is many people, swallow it.

I've got no interest in that side of it.

Curious then that you would bring it up.

 

[M Malice]

FWIW martinson , I enjoy reading your posts on the issue, adults should be able to make decisions about their own health and I support your right to do that.

 

[Jivlain]

I need to end it but that was about prevention after exposure, which obviously it cannot . It's not a preventative treatment.

As far as WHO studies go I think there's more than enough evidence out there that the organisation is questionable in the information it feeds out.

... you've got to the point of ending it without citing a single source, and yet you're still wondering why people aren't finding this persuasive.

 

[martinson]

COVID can be treated by a rum and coke a day.

I have done a heap of research.

I won't tell you what I used for my research.

Believe me.

I'm not asking anyone to believe me.

I've explained myself.

I'm happy for people to disbelieve me.

I've told you what I've used for my research . Re read.

I'm not an idiot. In fact apart from here I'm regarded as fairly smart.

But I'll wear the snips as a badge of honour.

And restrain myself from being likewise inclined.

 

[martinson]

FWIW martinson , I enjoy reading your posts on the issue, adults should be able to make decisions about their own health and I support your right to do that.

At last.

Thanks buddy.

That is all . I've made a personal decision about my health . I believe I've explained why. There are some private things I'm unable to elaborate on.

I'm not trying to persuade anybody .

 

[martinson]

Curious then that you would bring it up.

Because the articles you put up were about that.

 

[MSB ROYS]

Plus I don't think the personal vilification is necessary

And it seems I don't have one person who is remotely prepared to think I might be on to something.

Which is interesting.

I am a scientist who specialises in drug development who got their PhD over 25 years ago and have been working in industry and universities since then (several people on this site have met me so this is not BS). In particular, I have been working in the anti-infectives area for the last 15 years.

There is no convincing evidence that HQC improves covid-19 outcomes. A big issue is that it is difficult to do trials as nearly all people recover without any medical intervention. This makes running an appropriately powered placebo trial on a relatively small number of people impossible.

We will have vaccines available in about April next year but only time will tell how effective they are. IMO antibody therapies have a chance of being effective drugs, while we will probably use a combination of antiviral drugs in the future (similar to HIV); however, this will be awhile away.

 

[martinson]

I am a scientist who specialises in drug development who got their PhD over 25 years ago and have been working in industry and universities since then (several people on this site have met me so this is not BS). In particular, I have been working in the anti-infectives area for the last 15 years.

There is no convincing evidence that HQC improves covid-19 outcomes. A big issue is that it is difficult to do trials as nearly all people recover without any medical intervention. This makes running an appropriately powered placebo trial on a relatively small number of people impossible.

We will have vaccines available in about April next year but only time will tell how effective they are. IMO antibody therapies have a chance of being effective drugs, while we will probably use a combination of antiviral drugs in the future (similar to HIV); however, this will be awhile away.

All correct.

Except that I'm sceptical about a vaccine being available by April. Or at least one that will be widely available.

Btw I'm an investor in several AUS bios and some are already into trials/partnerships that will provide the solution . Of course it's done wonders for their share price . And of course they're just moon shoots with very little prospect of success.

 

[Jivlain]

Well, after all this fighting, how about something we can unify behind?

 

[martinson]

As we wait 5-8 years for a vaccine. We’ll keep an eye on that too.

Fact check.

Re read.

I said it takes 5-8 years minimum under normal circumstances.

And that Governments were throwing everything at this. There are now hundreds of 'trials' and ideas vs usually one or two trials proceeding in the myriad of other viruses.

So if anything can be found they'll find quickly against traditional benchmarks. Timing unknown

I'll restrain myself from the laughing emoji.

 

[M Malice]

Fact check.

Re read.

I said it takes 5-8 years minimum under normal circumstances.

And that Governments were throwing everything at this. There are now hundreds of 'trials' and ideas vs usually one or two trials proceeding in the myriad of other viruses.

So if anything can be found they'll find quickly against traditional benchmarks. Timing unknown

I'll restrain myself from the laughing emoji.

I'm certainly no expert on Covid19 but haven't we been trying for a coronavirus vaccine for around 20 years ie since SARS?

 

[briztoon]

Let's leave it at this . Why can't anyone just take on board what I've said ...

Because you are not a doctor or medical professional.

Nor have you offered up any peer reviewed articles to support your “advice”.

You’ve repeatedly advised not to believe what governments are telling us. However no one here is asking for government proof.

They are asking you for medical and scientific proof.

 

[dlanod]

I'm certainly no expert on Covid19 but haven't we been trying for a coronavirus vaccine for around 20 years ie since SARS?

This has been addressed, with supporting links, numerous times in this very thread. Basically it was a combination of deprioritisation (both funding and scheduling of trials), vaccine technology improving, and some teams being able to take advantage of the pre-work done by SARS teams.

Initially there was speculation that it was something inherent to coronaviruses, but some then took that speculation and posited it as if it was a fact instead of an unanswered question adding uncertainty to vaccine development.

 

[luthor]

I'm certainly no expert on Covid19 but haven't we been trying for a coronavirus vaccine for around 20 years ie since SARS?

I thought they gave up on a SARS vaccine because although it had a high mortality/fatality rate, it was contained to the point where it didn't warrant expending huge resources to find that vaccine. I believe it's still out there somewhere.

On the other hand Covid19 has a huge contagion rate and is scarier because it is so much harder to contain.

 

[Gadzorks]

If you take hydroxochloriquine and zithromax as soon as you get diagnosed you will recover quickly.

Already a couple of studies validated.

The problem is they wait until people are really sick and in ICU which is often too late.

So I’m on hydroxychloroquine for autoimmune cytokine storm prevention - the response to covid that is killing people.

The drug is a disease modifying drug and you need to be on it for about six months before it starts working effectively. Can’t see how it could possibly work in a few days if it’s targeting the same system.

I am however hoping that the trials to see if 3-6month use by health care workers prevents infection or escalation after infection shows it’s useful. Cause I need all the help I can get.

And I had to have a heart scan before I could be prescribed it, and I have to have heart scans yearly to monitor my heart for possible damage from the drug.

And yearly eye scans cause at doses over 400mg/day it can cause blindness. The trials for treating covid ranged from 800-1200mg/day

 

[DERRINALPHIL]

If you want some interesting info look at a youtube site Lockdown TV where you will hear "we don't know', "no evidence" etc. The two most interesting were shows with two mathematicians/ epidemiologists talking about suppression strategies and an interview with the bloke in charge of Sweden who continually says "its too early to say" all the time.

I have a great friend who has a PHd in virology who oversaw the flu vac here in Australia for many years. He tells me the problem is that URI vaccines will probably only be partially effective (like the Flu vac which I know is a different class of virus). A vaccine may provoke an antibody response that may be completely useless in warding off infection or reducing morbidity/mortality and lastly the response / immunity, if any, may be transient.

I had a Covid test last week. I didn't think I had any real chance of having the virus but as a dentist I did not feel I could take any risk at all. Many of my patients are elderly and you are in a very confined space, which we think is the perfect breeding ground for transmission.

I was negative which on consideration of only my own welfare was probably not the best result. I had a minor illness and a infection with the virus may have given me some immunity. We don't know yet if this is the usual outcome.

Now being a provocative prick I would like you to imagine Covid Parties, like the measles and mumps parties you read about. Being a healthy 60 year old I would like to get the virus this decade and so may accept an invite to such an event. We could have the Covid forward pocket at the GABBA!!!!! I would expect my private health insurance to pay for the seats, beers and pies during the match!!!

My hope is that the virus will mutate (look up genetic drift and shift) quickly into something harmless. Regression to the mean means this will happen, but when, is the question. The spanish flu went through once, then mutated into the real nasty, and it was this mutation that killed so many. The first pass was 'merely' a nasty flu.

 

[weevil]

If you take hydroxochloriquine and zithromax as soon as you get diagnosed you will recover quickly.

Already a couple of studies validated.

The problem is they wait until people are really sick and in ICU which is often too late.

I’ll say at the outset that I personally am not convinced either way on the effectiveness of Hydroxychloroquine. I’d lean towards it not working, but I’ve shifted my position multiple times.

I followed the debate about it for a few months, but the entire thing became so partisan and toxic I gave up in disgust.

Wave after wave after wave of junk studies are splashed all over the media breathlessly proclaiming to be definitive truth and bodies like the WHO have been forced into embarrassing backflips more than once because of their kneejerk reactions to them. All this is despite many of the studies having spectacular and really obvious flaws.

Like I say I stopped following the debate after it became a complete joke, but I gather that results from some actual authoritative studies are due in September...But take everything with a grain of salt, both sides are capable of producing petabytes of vile parochial bullshit per second on the subject.

Hydroxychloroquine may or may not work. Ideological warriors on both sides of politics may have wrecked any prospect of anyone ever finding out. But there are plenty of other treatments around (early but spectacular results for Interferon beta-1a) and deathrates around the world are down as we have gotten better at treating the disease. And of course, a number of teams around the world are doing brilliant work with Vaccines.

Like I say I lean towards it not working, but as loads of people here have asked for them, here are some studies and reports that say it does:

Prevalence and clinical correlates of COVID-19 outbreak among health care workers in a tertiary level hospital in Delhi

In this study, we summarize the epidemiological characteristics of COVID-19 outbreak among Healthcare workers (HCWs) in a tertiary care hospital and compared various parameters and preventive measures taken by positive HCWs to a comparable cohort of COVID negative HCWs. 52.1% of COVID-19...

www.medrxiv.org

Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid

Background Many different treatments were heavily administered to patients with COVID-19 during the peak of the pandemic in Madrid without robust evidence supporting them. Methods We examined the association between sixteen treatments in four groups (steroids, antivirals, antibiotics and...

www.medrxiv.org

DEFINE_ME

COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study - [v1]

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

As of May 27, 2020, there were over 1,678,843 confirmed cases of COVID-19 claiming more than 100,000 lives in the Unites States (CDC, 2020). Currently there is no known effective therapy or vaccine. The urgent need for therapeutic agents has resulted in repurposing and redeployment of...

www.ijidonline.com

Risk Factors for Mortality in Patients with COVID-19 in New York City - Journal of General Internal Medicine

Background New York City emerged as an epicenter of the coronavirus disease 2019 (COVID-19) pandemic. Objective To describe the clinical characteristics and risk factors associated with mortality in a large patient population in the USA. Design Retrospective cohort study. Participants 6493...

link.springer.com

Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection

Background Hydroxychloroquine sulphate (HCQ) is being scrutinized for repositioning in the treatment and prevention of SARS-Cov-2 infection. This antimalarial drug is also chronically used to treat patients with autoimmune diseases. Methods By analyzing the Portuguese anonymized data on private...

www.medrxiv.org

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis

In our institute in Marseille, France, we initiated early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early tre…

www.sciencedirect.com

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

medRxiv - the preprint server for biology, operated by openRxiv, a nonprofit organization dedicated to advancing scientific communication

www.medrxiv.org

HCQ beneficial as preventive drug: SMS doctors told ICMR

More than 4,300 healthcare workers including doctors and nurses have been given HCQ to help them prevent the infection as there are high chances of them getting infected while treating Covid patients.

health.economictimes.indiatimes.com

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France

Objective To assess the clinical effectiveness of oral hydroxychloroquine (HCQ) with or without azithromycin (AZI) in preventing death or leading to hospital discharge. Design Retrospective cohort study. Setting An analysis of data from electronic medical records and administrative claim data...

www.medrxiv.org

Henry Ford Health System still moving forward with hydroxychloroquine study

President Donald Trump had been hyping the antimalarial drug hydroxychloroquine as a potential coronavirus treatment, which led to Detroit heading up the first large-scale study...

www.metrotimes.com

A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications

The new SARS-CoV-2 infection named COVID-19 has severely hit our Health System. At the time of writing this paper no medical therapy is officially recommended or has shown results in improving the outcomes in COVID-19 patients. With the aim of diminishing the impact in Hospital admissions and...

www.medrxiv.org

Effet bénéfique de l’association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d’une étude observationnelle

Soixante-huit patients tous âgés de plus de 65 ans et diagnostiqués PCR-positif pour la COVID-19 ont reçu l’association hydroxychloroquine/azithromyci…

www.sciencedirect.com

Pre exposure Hydroxychloroquine Prophylaxis for COVID-19 in healthcare workers: a retrospective cohort

Background While several trials are ongoing for treatment of COVID-19, scientific research on chemoprophylaxis is still lacking even though it has potential to delay the pandemic allowing us time to complete research on vaccines. Methods We have conducted a cohort study amongst Health Care...

www.medrxiv.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2016638

Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 - [v1]

Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?

Arshad et al show evidence for a reduced mortality in Covid-19 patients taking hydroxychloroquine alone or with azithromycin in an observational study in USA (Arshad et al., 2020). Data on effectiveness and toxicity of hydroxychloroquine are controversial (Liu et al., 2020; Devaux et al., 2020...

www.ijidonline.com

The association between treatment with heparin and survival in patients with Covid-19

Objectives This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Methods Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the...

www.medrxiv.org

Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon

Background/Purpose We share our experience in COVID-19 pneumonia management at Saint George Hospital University Medical Center (SGHUMC) in Lebanon. In the absence of a standard of care, early diagnosis and opt-in therapy with Hydroxychloroquine and Azithromycin were offered. Methods We reviewed...

www.medrxiv.org

Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19

Abstract. Effective therapies are urgently needed for the SARS-CoV-2 pandemic. Chloroquine has been proved to have antiviral effect against coronavirus in

academic.oup.com

https://www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_the_use_of_HCQ_SARS_CoV2_infection.pdf

Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea

The authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the...

www.medrxiv.org

Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities

Importance Patients in long-term care facilities (LTCF) are at a high-risk of contracting COVID-19 due to advanced age and multiple comorbidities. Without effective treatments, outbreaks in such facilities will become commonplace and will result in severe morbidity and mortality. The...

www.medrxiv.org

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19 - PubMed

Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality. The most urgent need is to find effective treatments. We sought to determine whether hydroxychloroquine (HCQ) application may reduce the death risk of critically ill COVID-19 patients. In this...

pubmed.ncbi.nlm.nih.gov

https://www.medrxiv.org/content/10.1101/2020.05.05.20088757v1.full.pdf

DEFINE_ME

Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients

Background COVID-19 has rapidly emerged as a pandemic infection that has caused significant mortality and economic losses. Potential therapies and means of prophylaxis against COVID-19 are urgently needed to combat this novel infection. As a result of in vitro evidence suggesting zinc sulfate...

www.medrxiv.org

COVID-19 treatment trends over 6 weeks and 33,700 interviews

New York – May 7, 2020 – Week 6 results from Sermo’s COVID-19 Real Time Barometer with 6,150 physicians reveals COVID-19 treatment patterns among

www.sermo.com

Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study - [v2]

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France - PubMed

Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients.

pubmed.ncbi.nlm.nih.gov

Clam Reports

Clam Reports is a dedicated team of international reporters, journalists, and developers. We translate and compile local news sources from various languages into comprehensive English reports, delivering accurate and swift information to our users.

www.tellerreport.com

Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19

OBJECTIVE: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also called COVID-19, has caused a pandemic which has swiftly involved

www.europeanreview.org

(PDF) COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes

PDF | Background There is a growing need for information regarding the recent coronavirus disease of 2019 (Covid-19). We present a comprehensive report... | Find, read and cite all the research you need on ResearchGate

www.researchgate.net

Countries which Primarily Use Antimalarial Drugs As COVID-19 Treatment See Slower Dynamic of Daily Deaths

COVID-19 (Coronavirus Disease-2019) is an international public health problem with a high rate of severe clinical cases. Several treatments are currently being

papers.ssrn.com

Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? - PubMed

In the context of the ongoing global outbreak of coronavirus disease 2019 (COVID-19), management of exposure events is a concern. Long-term care hospitals (LTCHs) are particularly vulnerable to cluster outbreaks because facilities for patient isolation and healthcare personnel to care for these...

pubmed.ncbi.nlm.nih.gov

Dropbox

www.dropbox.com

Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19) - PubMed

Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Increasing evidence obtained from completed clinical studies indicates...

pubmed.ncbi.nlm.nih.gov

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration.We conducted an uncontrolled, non-comparative, observ…

www.sciencedirect.com

Treating COVID-19 with Chloroquine

A novel coronavirus disease 2019 (COVID-19) emerged around December 2019 in Wuhan, China and has spread rapidly worldwide (Lu et al., 2020). Until March 27

academic.oup.com

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Aims Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods From...

www.medrxiv.org

https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf

https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 - PMC

www.ncbi.nlm.nih.gov

http://rs.yiigle.com/yufabiao/1182323.htm

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

www.jstage.jst.go.jp

Antimalarial drug confirmed effective on COVID-19 - Xinhua | English.news.cn

 

[ZoBlitz]

Prevalence and clinical correlates of COVID-19 outbreak among health care workers in a tertiary level hospital in Delhi

In this study, we summarize the epidemiological characteristics of COVID-19 outbreak among Healthcare workers (HCWs) in a tertiary care hospital and compared various parameters and preventive measures taken by positive HCWs to a comparable cohort of COVID negative HCWs. 52.1% of COVID-19...

www.medrxiv.org

Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid

Background Many different treatments were heavily administered to patients with COVID-19 during the peak of the pandemic in Madrid without robust evidence supporting them. Methods We examined the association between sixteen treatments in four groups (steroids, antivirals, antibiotics and...

www.medrxiv.org

COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study - [v1]

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

medRxiv - the preprint server for biology, operated by openRxiv, a nonprofit organization dedicated to advancing scientific communication

www.medrxiv.org

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France

Objective To assess the clinical effectiveness of oral hydroxychloroquine (HCQ) with or without azithromycin (AZI) in preventing death or leading to hospital discharge. Design Retrospective cohort study. Setting An analysis of data from electronic medical records and administrative claim data...

www.medrxiv.org

A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications

The new SARS-CoV-2 infection named COVID-19 has severely hit our Health System. At the time of writing this paper no medical therapy is officially recommended or has shown results in improving the outcomes in COVID-19 patients. With the aim of diminishing the impact in Hospital admissions and...

www.medrxiv.org

Pre exposure Hydroxychloroquine Prophylaxis for COVID-19 in healthcare workers: a retrospective cohort

Background While several trials are ongoing for treatment of COVID-19, scientific research on chemoprophylaxis is still lacking even though it has potential to delay the pandemic allowing us time to complete research on vaccines. Methods We have conducted a cohort study amongst Health Care...

www.medrxiv.org

Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon

Background/Purpose We share our experience in COVID-19 pneumonia management at Saint George Hospital University Medical Center (SGHUMC) in Lebanon. In the absence of a standard of care, early diagnosis and opt-in therapy with Hydroxychloroquine and Azithromycin were offered. Methods We reviewed...

www.medrxiv.org

Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea

The authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the...

www.medrxiv.org

Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities

Importance Patients in long-term care facilities (LTCF) are at a high-risk of contracting COVID-19 due to advanced age and multiple comorbidities. Without effective treatments, outbreaks in such facilities will become commonplace and will result in severe morbidity and mortality. The...

www.medrxiv.org

https://www.medrxiv.org/content/10.1101/2020.05.05.20088757v1.full.pdf

Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients

Background COVID-19 has rapidly emerged as a pandemic infection that has caused significant mortality and economic losses. Potential therapies and means of prophylaxis against COVID-19 are urgently needed to combat this novel infection. As a result of in vitro evidence suggesting zinc sulfate...

www.medrxiv.org

Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study - [v2]

(PDF) COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes

PDF | Background There is a growing need for information regarding the recent coronavirus disease of 2019 (Covid-19). We present a comprehensive report... | Find, read and cite all the research you need on ResearchGate

www.researchgate.net

Countries which Primarily Use Antimalarial Drugs As COVID-19 Treatment See Slower Dynamic of Daily Deaths

COVID-19 (Coronavirus Disease-2019) is an international public health problem with a high rate of severe clinical cases. Several treatments are currently being

papers.ssrn.com

Dropbox

www.dropbox.com

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Aims Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods From...

www.medrxiv.org

Not making a determination on the research but just thought I'd mention as someone who works in the publication collection field for a university, that the papers I've quoted above haven't yet gone through a peer review acceptance process through a journal so there's no confirmation of the validity of the research at this point. Two of them also seem to have been withdrawn ("Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea" and "Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?") for whatever reason.

Pre-print sites (medrxiv and preprints.org are main examples here) are great for providing open access outlets for new research, but always take it with a grain of salt until the work has been published by a journal that has a rigorous peer review process (look out for quality publishers such as Elsevier or Springer or Oxford University Press etc etc)

By the way, this is the last place I thought I'd be using my work knowledge...

 

[weevil]

Not making a determination on the research but just thought I'd mention as someone who works in the publication collection field for a university, that the papers I've quoted above haven't yet gone through a peer review acceptance process through a journal so there's no confirmation of the validity of the research at this point. Two of them also seem to have been withdrawn ("Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea" and "Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?") for whatever reason.

Pre-print sites (medrxiv and preprints.org are main examples here) are great for providing open access outlets for new research, but always take it with a grain of salt until the work has been published by a journal that has a rigorous peer review process (look out for quality publishers such as Elsevier or Springer or Oxford University Press etc etc)

By the way, this is the last place I thought I'd be using my work knowledge...

I'm absolutely in no way advocating for the quality or otherwise of any of them. Like I say, the massive majority of all studies I have seen have been total junk in one way or another.

Data show panic and disorganization dominate the study of Covid-19 drugs

A new STAT analysis shows about 38% of the studies registered to study Covid-19 treatments have not actually begun enrolling patients.

www.statnews.com

 

[ZoBlitz]

I'm absolutely in no way advocating for the quality or otherwise of any of them. Like I say, the massive majority of all studies I have seen have been total junk in one way or another.

Data show panic and disorganization dominate the study of Covid-19 drugs

A new STAT analysis shows about 38% of the studies registered to study Covid-19 treatments have not actually begun enrolling patients.

www.statnews.com

Oh yeah, I understand. Just thought it might be a good opportunity to explain the publishing process in case anyone wanted more context to research they read online.

 

[M Malice]

This has been addressed, with supporting links, numerous times in this very thread. Basically it was a combination of deprioritisation (both funding and scheduling of trials), vaccine technology improving, and some teams being able to take advantage of the pre-work done by SARS teams.

Initially there was speculation that it was something inherent to coronaviruses, but some then took that speculation and posited it as if it was a fact instead of an unanswered question adding uncertainty to vaccine development.

It doesn't surprise me that I do not recall this. Excuse the seniors moment.